ABSTRACT
Background Immune checkpoint inhibitors (ICIs) have significantly improved patient survival outcomes across various cancer types. However, their use is often associated with immune-related adverse events (irAEs), posing challenges in clinical management. Understanding the incidence, severity, and risk factors of irAEs is critical for optimizing ICI therapy and minimizing adverse outcomes.
Objective This study aimed to identify and evaluate risk factors for immune-related adverse events (irAEs) among patients receiving ICIs, focusing on patient demographics, comorbidities, cancer types, and ICI regimens. Additionally, we sought to examine the incidence, severity, and organ-specific patterns of irAEs to guide personalized management strategies.
Methods This retrospective cohort study utilized real-world data from the OneFlorida+ Clinical Research Network, including 9,193 adult patients who received ICIs between January 2018 and December 2022. Patients were categorized based on whether they developed irAEs within one year of initiating ICI therapy. Multivariable logistic regression was employed to identify risk factors for irAEs, adjusting for key covariates such as age, sex, cancer type, smoking status, and comorbidities. Kaplan-Meier survival analysis and cumulative incidence functions were applied to evaluate time to irAE event and overall incidence, stratified by irAE severity, cancer type, and ICI regimens.
Results Of the 6,526 patients included in the final analysis, 56.2% developed irAEs within one year of ICI treatment, including 284 severe cases. Female and younger patients (ages 18-29) were at higher risk of developing irAEs, while comorbidities such as myocardial infarction, congestive heart failure, and renal disease significantly increased irAE risk. In contrast, dementia was associated with a reduced risk of irAEs. Patients treated with combined CTLA4+PD(L)1 inhibitors exhibited a 35% higher risk of irAEs compared to PD-1 inhibitors alone (OR: 1.35, 95% CI: 1.14–1.60, P < 0.001). Cancer type also influenced irAE risk, with breast cancer (OR: 2.36, 95% CI: 1.57–3.60, P < 0.001) and hematological cancer (OR: 2.61, 95% CI: 1.40–5.14, P = 0.004) associated with higher risk compared to melanoma, whereas brain cancer had a reduced risk (OR: 0.55, 95% CI: 0.32–0.92, P = 0.025). Survival analysis revealed that irAE severity significantly impacts both the timing of irAE onset (P = 0.038) and overall survival (P < 0.0001). While treatment regimens significantly influenced irAE-free survival in multi-site cancers (P = 0.02) and overall survival in kidney cancer (P = 0.0011), their effects were less pronounced in other cancer types.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the National Institute of General Medical Sciences of the National Institutes of Health (R35GM151089).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study has been approved by the University of Florida Institutional Review Board (IRB# 201702876).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Abbreviations
- ICI
- immune checkpoint inhibitors ir
- AE
- immune-related adverse events
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.